Jim Cramer’s Must-Watch List: 10 Stocks to Look After

3. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors: 57

Jim Cramer discussed Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a biotech company that will be presenting at the European Society for Medical Oncology annual meeting on Monday. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) will highlight its impressive oncology portfolio, which includes treatments for advanced melanoma and non-small cell lung cancer. These drugs have expanded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s business, but Cramer is particularly interested in the company’s potential obesity drug.

“On Monday, Regeneron is presenting. That’s a biotech company holding an analyst meeting at the European Society for Medical Oncology annual meeting, where they’ll showcase their oncology portfolio, which is beautiful, including forms to treat advanced melanoma and non-small cell lung cancer. These are important drugs that have helped diversify Regeneron’s business, but I’m still focused on the company’s obesity drug candidate.

When I was at the JP Morgan Healthcare Conference in San Francisco earlier this year, I spoke with Regeneron CEO Len Schleifer, an old friend of the show who was one of our first guests. He was confident that his company might have a weight loss drug that only attacks fat, not muscle. That’s huge, as people who take GLP-1s experience muscle atrophy unless they work out pretty consistently. I think this drug would be an instant success if it can get through the clinical trials. Right now, it’s too early in the process to take anything as gospel.”

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands out as a strong investment choice due to its solid financial results, promising oncology pipeline, and robust product lineup. In Q2 2024, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw a 12% increase in revenue compared to the previous year, reaching $3.5 billion, thanks to strong sales of Dupixent and the successful launch of EYLEA HD.

Its revenue from collaborations with Sanofi also grew by 21%, enhancing its financial health. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s oncology pipeline is impressive, with its PD-1 inhibitor Libtayo performing well and ongoing research into new treatments like fianlimab and davutamig. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s substantial investment in research and development, along with strategic partnerships with Sanofi and Bayer, highlights its commitment to innovation.